These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 37155018)

  • 1. Orexin pathway in Parkinson's disease: a review.
    Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Zaafar D; Batiha GE
    Mol Biol Rep; 2023 Jul; 50(7):6107-6120. PubMed ID: 37155018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential.
    Liu C; Xue Y; Liu MF; Wang Y; Chen L
    Neurochem Int; 2020 Sep; 138():104754. PubMed ID: 32422324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Role of Orexinergic Neurons in Parkinson's Disease.
    Kumar S; Behl T; Sehgal A; Singh S; Sharma N; Bhatia S; Al-Harassi A; Abdel-Daim MM; Bungau S
    Neurotox Res; 2021 Dec; 39(6):2141-2153. PubMed ID: 34495449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orexinergic neurons are involved in the chemosensory control of breathing during the dark phase in a Parkinson's disease model.
    Oliveira LM; Falquetto B; Moreira TS; Takakura AC
    Exp Neurol; 2018 Nov; 309():107-118. PubMed ID: 30110606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease.
    Stanojlovic M; Pallais JP; Kotz CM
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypocretin (orexin) cell loss in Parkinson's disease.
    Thannickal TC; Lai YY; Siegel JM
    Brain; 2007 Jun; 130(Pt 6):1586-95. PubMed ID: 17491094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Several neuropeptides involved in parkinsonian neuroprotection modulate the firing properties of nigral dopaminergic neurons.
    Chen L; Liu C; Xue Y; Chen XY
    Neuropeptides; 2023 Jun; 99():102337. PubMed ID: 37087783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexin-B exerts excitatory effects on nigral dopaminergic neurons and alleviates motor disorders in MPTP parkinsonian mice.
    Bian K; Liu C; Wang Y; Xue Y; Chen L
    Neurosci Lett; 2021 Nov; 765():136291. PubMed ID: 34666119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity.
    Stanojlovic M; Pallais Yllescas JP; Vijayakumar A; Kotz C
    Mol Neurobiol; 2019 Dec; 56(12):8435-8450. PubMed ID: 31250383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glymphatic System Dysfunction and Sleep Disturbance May Contribute to the Pathogenesis and Progression of Parkinson's Disease.
    Scott-Massey A; Boag MK; Magnier A; Bispo DPCF; Khoo TK; Pountney DL
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson's disease patients.
    Huang S; Zhao Z; Ma J; Hu S; Li L; Wang Z; Sun W; Shi X; Li M; Zheng J
    Neurosci Lett; 2021 Jan; 741():135480. PubMed ID: 33161104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy.
    Ali NH; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; AlAseeri AA; Alruwaili M; Saad HM; Batiha GE
    J Cell Mol Med; 2024 May; 28(10):e18368. PubMed ID: 38752280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit.
    Alharbi B; Al-Kuraishy HM; Al-Gareeb AI; Elekhnawy E; Alharbi H; Alexiou A; Papadakis M; Batiha GE
    Eur J Med Res; 2024 Mar; 29(1):205. PubMed ID: 38539252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Mechanism of SNHG8/Microrna-421-3p/Sorting Nexin 8 Axis on Dopaminergic Neurons in Substantia Nigra in a Mouse Model of Parkinson's Disease.
    Zhou S; Zhou X; Jiang Z; Ma J; Li Y; Qian Z; Li H
    Neurochem Res; 2023 Mar; 48(3):942-955. PubMed ID: 36401052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease.
    Stanojlovic M; Pallais JP; Lee MK; Kotz CM
    Mol Brain; 2019 Oct; 12(1):87. PubMed ID: 31666100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.
    Aimé P; Sun X; Zareen N; Rao A; Berman Z; Volpicelli-Daley L; Bernd P; Crary JF; Levy OA; Greene LA
    J Neurosci; 2015 Jul; 35(30):10731-49. PubMed ID: 26224857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's Disease Risk and Hyperhomocysteinemia: The Possible Link.
    Al-Kuraishy HM; Al-Gareeb AI; Elewa YHA; Zahran MH; Alexiou A; Papadakis M; Batiha GE
    Cell Mol Neurobiol; 2023 Aug; 43(6):2743-2759. PubMed ID: 37074484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques.
    Bensaid M; Tandé D; Fabre V; Michel PP; Hirsch EC; François C
    Eur J Neurosci; 2015 Jan; 41(1):129-36. PubMed ID: 25328140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.